Abstract
Abstract
Background
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a rare but serious side effect of nitrogen-containing bisphosphonate drugs (N-BPs) frequently prescribed to reduce skeletal-related events in bone malignancies and osteoporosis. BRONJ is associated with abnormal oral wound healing after dentoalveolar surgery and tooth extraction. We previously found that N-BP chemisorbed to bone mineral hydroxyapatite was dissociated by secondary applied N-BP. This study investigated the effect of the surface equilibrium-based removal of N-BP from jawbone on tooth extraction wound healing of zoledronate (ZOL)-treated mice.
Methods
A pharmacologically inactive N-BP derivative (the 4-pyridyl isomer of risedronate equipped with a near-infrared 800CW fluorescent imaging dye, 800CW-pRIS) was designed and synthesized. 800CW-pRIS was intra-orally injected or topically applied in a deformable nano-scale vesicle formulation (DNV) to the palatal tissue of mice pretreated with ZOL, a potent N-BP. The female C56BL6/J mice were subjected to maxillary molar extraction and oral wound healing was compared for 800CW-pRIS/ZOL, ZOL and untreated control groups.
Results
800CW-pRIS is confirmed to be inactive in inhibiting prenylation in cultured osteoclasts while retaining high affinity for hydroxyapatite. ZOL-injected mice exhibit delayed tooth extraction wound healing with osteonecrosis relative to the untreated controls. 800CW-pRIS applied topically to the jaw one week before tooth extraction significantly reduces gingival oral barrier inflammation, improves extraction socket bone regeneration, and prevents development of osteonecrosis in ZOL-injected mice.
Conclusions
Topical pre-treatment with 800CW-RIS in DNV is a promising approach to prevent the complication of abnormal oral wound healing associated with BRONJ while retaining the anti-resorptive benefit of legacy N-BP in appendicular or vertebrate bones.
Funder
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research
Tohoku University
MEXT | Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. O’Carrigan, B. et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst. Rev 10, CD003474 (2017).
2. Finianos, A. & Aragon-Ching, J. B. Zoledronic acid for the treatment of prostate cancer. Expert Opin. Pharmacother. 20, 657–666 (2019).
3. Mhaskar, R., Kumar, A., Miladinovic, B. & Djulbegovic, B. Bisphosphonates in multiple myeloma: an updated network meta-analysis. Cochrane Database Syst. Rev. 12, CD003188 (2017).
4. Fink, H. A. et al. Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. Ann. Intern. Med. 171, 37–50 (2019).
5. Russell, R. G. Bisphosphonates: mode of action and pharmacology. Pediatrics 119, S150–S162 (2007).